Avalo Therapeutics Pipeline
| Drug | Indication | Phase |
|---|
| AVTX-002 | Non-COVID-19 Acute Lung Injury / ARDS | Phase 2b |
| AVTX-008 | Inflammatory Bowel Disease | Preclinical |
| AVTX-803 | Leukocyte Adhesion Deficiency Type II | Phase 2 |
| AVTX-802 | PMM2-CDG (Congenital Disorder of Glycosylation) | Phase 2 |